Fund Holdings — Kynam Capital Management, LP

Total Portfolio Value:
$1.81B
Total Bought:
$243.76M
Total Sold:
$114.84M
Net Transaction:
+$128.92M
Notable People:
Kynam Capital Management Gp,
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Legend Biotech CorporationADS(LEGN)3,001,2059,154,389+6,153,184$86.67M$182.08M10.08%+$95.41M
Celldex Therapeutics, Inc.(CLDX)5,322,9085,066,051-256,857$198.07M$164.19M9.09%-$33.87M
Syndax Pharmaceuticals, Inc.(SNDX)8,050,9598,150,959+100,000$175.99M$153.24M8.48%-$22.76M
Vaxcyte, Inc.(PCVX)2,922,3352,607,964-314,371$169.88M$148.39M8.22%-$21.48M
Viridian Therapeutics, Inc.(VRDN)6,453,8776,148,000-305,877$118.56M$126.59M7.01%+$8.03M
Cogent Biosciences, Inc.(COGT)3,667,0973,792,289+125,192$141.92M$121.43M6.72%-$20.49M
Travere Therapeutics, Inc.(TVTX)2,000,0002,000,0000$113.62M$117.76M6.52%+$4.14M
UroGen Pharma Ltd.(URGN)2,434,2072,434,2070$89.58M$98.90M5.48%+$9.32M
Vera Therapeutics, Inc.CL A(VERA)2,890,0593,000,000+109,941$124.01M$96.87M5.36%-$27.14M
Beam Therapeutics Inc.(BEAM)2,840,7923,933,894+1,093,102$97.50M$96.18M5.33%-$1.31M
Cytomx Therapeutics Inc.21,703,09321,140,726-562,367$81.39M$57.50M3.18%-$23.88M
MBX Biosciences, Inc.(MBX)934,799934,7990$51.60M$54.80M3.03%+$3.20M
Summit Therapeutics Inc.(SMMT)1,200,0003,000,000+1,800,000$17.48M$50.73M2.81%+$33.25M
Relay Therapeutics, Inc.(RLAY)3,300,0002,751,500-548,500$61.74M$49.66M2.75%-$12.08M
Cullinan Therapeutics Inc3,114,1323,114,1320$56.71M$47.80M2.65%-$8.91M
Immunocore Holdings plcADS(IMCR)1,375,0001,375,0000$43.66M$41.65M2.31%-$2.01M
Nurix Therapeutics, Inc.(NRIX)1,194,7571,194,7570$28.98M$28.33M1.57%-$657.1K
Pharvaris N V
COM
661,795824,843+163,048$22.88M$26.16M1.45%+$3.28M
Burning Rock Biotech LtdADS1,238,5631,238,5630$10.52M$21.84M1.21%+$11.32M
BioCryst Pharmaceuticals, Inc.(BCRX)2,522,6602,522,6600$25.23M$21.01M1.16%-$4.21M
Surrozen Inc0486,252+486,252$0$15.65M0.87%+$15.65M
Sutro Biopharma Inc872,558872,5580$28.97M$14.06M0.78%-$14.91M
Xenon Pharmaceuticals Inc.(XENE)0280,000+280,000$0$10.41M0.58%+$10.41M
Evommune Inc01,200,000+1,200,000$0$9.91M0.55%+$9.91M
Prelude Therapeutics Inc2,415,0872,311,955-103,132$12.87M$9.04M0.50%-$3.83M
Geron Corp6,836,3186,836,3180$8.75M$8.41M0.47%-$341.8K
Parabilis Medicines Inc250,000250,0000$6.84M$8.07M0.45%+$1.23M
Alector Inc3,808,4944,308,494+500,000$7.66M$7.97M0.44%+$315.6K
Amarin Corp PlcADR532,982532,9820$8.50M$6.93M0.38%-$1.57M
Harrow, Inc.(HROW)0124,655+124,655$0$3.84M0.21%+$3.84M
Caribou Biosciences Inc2,503,3022,503,3020$4.41M$3.18M0.18%-$1.23M
Proqr Thrapeutics N VSHS EURO
SHS EURO
1,566,3171,566,3170$2.91M$2.60M0.14%-$313.3K
Engene Therapeutics Inc457,855457,8550$792.1K$915.7K0.05%+$123.6K
Traws Pharma Inc84,40084,4000$71.2K$50.1K0.00%-$21.1K
Candel Therapeutics, Inc.(CADL)96,7410-96,741$996.4K$0—-$996.4K
Insmed Incorporated(INSM)100,0000-100,000$10.66M$0—-$10.66M
Page 1 of 1
Kynam Capital Management, LP — 13F Holdings — Q3 2026 | TickerTrail